This research presents an analytical technology for highly efficient, high-resolution, and highyield fractionation of compounds after gas chromatography (GC) separations. The technology is straightforward, does not require sophisticated cold traps or adsorbent traps, and allows collecting large numbers of fractions during a GC run. The technology is based on direct infusion of a carrier solvent at the end of the GC column, where infusion takes place in the GC oven. Pentane and hexane used as carrier solvent showed good results. Acetonitrile also showed good results as a more polar carrier solvent. Development and optimization of the technology is described, followed by demonstration in a high-throughput effect directed analysis setting toward dioxin receptor bioactivity. The GC fractionation setup was capable of collecting fractions in the second range. As a result, fractionated compounds could be collected into one or two fractions when 6.5 s resolution fractionation was performed. Subsequently, mixtures containing polycyclic aromatic hydrocarbons, of which some are bioactive toward the dioxin receptor, were profiled with a mammalian gene reporter assay. After fractionation into 96-well plates, we used our new approach for direct cell seeding onto the fractions prior to assaying which allowed dioxin receptor bioactivity to be measured directly after fractionation. The current technology represents a great advance in effect directed analysis for environmental screening worldwide as it allows combining the preferred analytical separation technology for often non-polar environmental pollutants with environmentally relevant bioassays, in high resolution.
Introduction
Current state-of-the-art fractionation of compounds after gas chromatography (GC) mostly requires complicated setups and only allows automated collection of a very limited number of fractions, usually only six, utilizing complicated cryo-trapping or adsorbent collection vessels [1] [2] [3] [4] [5] [6] [7] [8] . As a result, postcolumn fractionation after liquid chromatography (LC) is used more frequently, even if GC is superior to LC for the mixtures to be separated and fractionated. Fractionation in LC is straightforward. LC fractionation setups are widespread when off-line analysis is to be performed after separation, e.g., for off-line bioassays in effect-directed analysis (EDA). The principle of EDA is to sequentially reduce the complexity of environmental, food, and/or technical mixtures by multiple fractionations (usually with low resolution [that is in the minutes range]) guided by biological activity [9] [10] [11] . Commonly used EDA approaches in environmental settings are directed toward the dioxin and estrogen receptors [10] [11] [12] . The biological activity found using EDA is to be correlated to the compound identities, mostly established with mass spectrometry (MS), but possibly assisted by nuclear magnetic resonance (NMR) and other spectroscopic techniques [12] [13] [14] . As lowresolution fractionation often results in fractions that still contain many compounds, each bioactive fraction has to be fractionated further, and the next series of fractions is to be tested again in the bioassay. This iterative fractionation strategy often fails to identify the bioactive compounds since the bioactive fractions remain too complex for chemical identification, or compounds degrade or adhere to sample vials during the process. High-resolution fractionation after LC as described by Giera et al. [15] and Kool et al. [16] provided an advancement as fractions collected are in the seconds rather than minutes range. This allows a direct reconstruction of high-resolution bioactivity chromatograms and provides improved correlation between bioactivity and mass (as obtained by parallel postcolumn MS analysis) [15, 16] . Many compound classes, relevant in EDA, such as polycyclic aromatic hydrocarbons (PAHs), pesticides, and mineral oils are preferably analyzed by GC. Moreover, certified GC methodologies have been established in this area. Given the current limitations in GC fractionation, we decided to develop an alternative strategy. In this paper, we describe the development, optimization, validation, and application of a new GC fractionation strategy. Via a Y-shaped connector, positioned at the end of the GC column but still in the GC oven [17] , a carrier solvent is continuously infused and mixed with the carrier gas flow. The gasliquid mixture with the eluting compounds is collected in vials or, via a robotic device, in a 96-well microtiter plate (MTP). The volatile carrier solvent evaporates and leaves the fractionated compounds behind. In this way, the number of fractions can be drastically increased over currently available technology; fractions with seconds-range resolution can be collected. The fractionation technology developed was demonstrated in an environmental setting. Endocrine-disrupting pollutants in mixtures were identified as bioactives toward the dioxin receptor by using a mammalian cellular gene reporter assay as readout. In order to eliminate additional handling steps and prevent compound dilution, cells were seeded and grown postfractionation, directly onto the collected fractions.
Experimental Chemicals
Development and optimization of the new GC fractionation system was performed using an in-house prepared stock solution (M12) containing the 12 halogenated compounds dissolved in n-hexane at a 10 
Procedure and Instrumentation Used for Development and Optimization
Separation Mixture M12 was separated using a system as illustrated in Figure 1 . The GC part of the system consisted of a Hewlett-Packard (Agilent Technologies, Palo Alto, CA, U.S.A.) HP6890 series GC oven (1) and auto injector (3), controlled by HP GC ChemStation 7.0 software. The FID detector (2) was not used in our setup. The split/splitless injection port (4) was equipped with a 11-mm Agilent septum and a Restek Sky 4.0 mm I.D. single taper/gooseneck inlet liner (5) (4.0 mm × 6.5 mm × 78.5 mm; Interscience, Breda, The Netherlands). The capillary column (6) was a Varian FactorFour VF-5 ms column (5% phenyl/95% dimethylpolysiloxane; 30 m × 0.37 mm × 250 μm I.D). The column exit was connected to a Restek Siltek MXT Y-union (7).
The injection volume of M12 was 1 μL, and the GC injection temperature was 300 °C using splitless mode. The purging of the split vent was started 2.0 min after injection with 20 mL/min helium. The GC oven was programmed from 65 °C (hold time 2.0 min) to 300 °C (hold time 8.0 min) at 15 °C/min. Praxair 5.0 grade helium (Vlaardingen, The Netherlands) was used as carrier gas and was kept at a constant column flow rate of 2.5 mL/min during the entire run, resulting in a head pressure of 170 kPa at 65 °C.
Preparation for Fractionation
As shown in Figure 1 , the carrier gas from the GC column (8) was continuously mixed with a flow of n-hexane (or another solvent), which served as carrier liquid (9) System setup of the GC fractionation system. Prior to the chromatographic separation, the GC oven (1) is programmed, and an optional standard (2) holding the cooling device is positioned. The sample is injected using an autoinjector (3) with splitless inlet (4) . Through evaporation in the inert liner (5) the solvent plus analytes are transferred to the column (6), where they are separated and led through the Y-union (7) at the exit of the capillary column (8) . In the Y-union, the carrier gas containing analytes is mixed with a carrier fluid entering from the liquid pump inlet (9) . The fluid (11) is pumped through a carrier line (13) (14) (15) by a syringe pump (10) . The carrier line consists of a zero-dead-volume connector piece (12) connected to PEEK tubing (13) which in turn is connected to a deactivated capillary (15) by another zero-dead-volume connector (14) . The mixture of gas and fluid exits through the third opening of the Y-union, after which it can immediately be cooled using an optional stationary capillary cooler (16) held by a clamp (2) . The direct or ambient cooled flow is then led to the X,Y,Z fractionation stage (20) via the outlet of the deactivated capillary (17) . The arm of the X,Y,Z fractionation stage (19) moves the exit of the outlet capillary in a serpentine pattern over a well plate (21) held by an in-housemade well plate holder (22) .
Fraction Collection and Recovery Analysis
Once outside of the GC oven, the outlet capillary was cooled by indirect heat exchange with the ambient air at room temperature (besides ambient air, also solid carbon dioxide (CO 2 , −80 °C) and a solid CO 2 /acetonitrile mixture (−40 °C) were tested using an in-house-built cooling trap). The exit of the outlet capillary (18) ppm) lindane was added as IS. All fractions were analyzed by GC with electron-capture detection (GC-ECD). Detailed information can be found in the Supplementary material.
Postfractionation Bioassay Analysis

GC Fractionation
For fractionation, modifications to the GC program and settings were made. This information and relevant information on the parallel GC-MS analysis of the PAH standards and the CRM-535 sample can be found in the Supplementary material.
Bioassay Protocol and Analysis
Bioassay analysis was performed on Greiner polystyrene MTPs. First, the wells were coated by spotting 2.5 μL of 10% DMSO in water solution with a Thermo Scientific Multidrop Combi nL (Breda, The Netherlands), followed by evaporation of the water fraction under a nitrogen stream. This results in an end concentration of 0.25% DMSO after adding the cells. Fractions were collected onto the MTPs in a serpentine pattern, excluding the outer wells.
Plates were dried under a nitrogen stream and stored at −20 °C until further use. The potency to activate the dioxin or arylhydrocarbon receptor (AhR) was measured in the DR-LUC bioassay, consisting of the rat hepatoma cell line H4IIE, stably transfected with a luciferase construct under the transcriptional control of dioxin-responsive elements (DREs) [18] . Cell culturing and exposure was performed according to Murk et al. [19] with modifications. Cells were cultured in α-minimum essential medium (Gibco, Bleiswijk, The Netherlands) supplemented with 10% fetal bovine serum (Sigma-Aldrich) and penicillin/streptomycin (Gibco). Prior to exposure, cells were suspended in complete medium. The 96-well MTPs with collected GC fractions were directly filled with the cell suspension (100 μL per well). In this way, cells were seeded postfractionation and were directly exposed to the fractions while also attaching to the bottoms of the wells. After exposure for 48 h, cells were visually checked for cytotoxic effects. Then, cells were lysed and measured for luciferase activity expressed in relative light units (RLU), according to Murk et al. [19] . The activities found were plotted against retention times of the collected fractions to obtain reconstructed bioactivity chromatograms.
Results and Discussion
This study describes a new approach for fractionation of compounds after GC. Figure 1 shows a schematic diagram of the setup. The outlet capillary from the Y-union is led to a fractionator holding a 96-well MTP in which the fractions are collected with a predetermined fractionation resolution (s/well). For optimization, compound recovery and fractionation resolution was evaluated using a synthetic mixture (M12, 1 μL of 10 -5 M) and subsequent analysis of fractions by GC-ECD. The parameters under study were carrier solvent type, carrier solvent flow rate, helium pressure/flow rate, outlet carrier capillary length and diameter, position of the Y-union in GC oven, and effects of outlet carrier capillary cooling. Some parameters were evaluated by mixing the solvent and collecting the complete GC separation into one vial. The biological application involved environmental profiling for AhR activating compounds using the dioxin-responsive luciferase reporter gene (DR-LUC) bioassay, which is at present the best screening method for dioxins and dioxin-like compounds [20] [21] [22] .
Parameter Optimization
Hexane, pentane, methanol, and acetonitrile were each tested as carrier solvent at a flow rate of 170.0 μL/min by collecting the GC separation into one vial). With methanol, an average compound recovery of 39 ± 2% was found, whereas hexane, pentane and acetonitrile gave recoveries of 80 ± 2%, 85 ± 3%, and 90 ± 2%, respectively. When using n-pentane (boiling point of 36 °C) instead of hexane (boiling point of 68 °C) for fractionation on MPTs, very rapid evaporation of n-pentane is followed by evaporation of fractionated early eluting compounds. Acetonitrile was shown to dissolve plasticizers in the MTPs used. Thus, hexane was chosen as carrier solvent.
To evaluate the drying time, 200 μL portions of M12 were deposited in various nonadjacent wells. The wells were then allowed to dry under nitrogen stream for different time intervals, ranging from evaporated to dryness (after 2 min) to 60 min. GC-ECD showed an (expected) correlation between elution time and evaporation profile (see Figure S1 in the Supplementary material). The early eluting compounds largely decreased in recovery even after a few minutes of drying, whereas the later-eluting compounds showed little or no recovery loss, and only after complete evaporation of hexane. Different carrier solvent flow rates (84, 170, 340, and 700 μL/min) were tested at a low resolution (30 s/well) to determine the optimum flow rate. High solvent flow rates caused a notable side effect: delay in compound elution due to backpressure effects. There appeared not to be a distinct optimum flow rate as recoveries were similar for the range tested (see Supplementary material Figure S2a ). The last eluting compound, TM, showed a remarkably low recovery with a high deviation, which might be due to its poor solubility in hexane and its high boiling point ( 594 °C). Similar broadening effects and low recovery, however, were observed for TM when using the more polar carrier solvent, acetonitrile. In a subsequent high-resolution fractionation experiment (6.5 s/well), only the first five peaks were collected in order to reduce the number of fractions to be reanalyzed. The results (displayed in the Supplementary material Figure S2b ) indicate similar recoveries for the compounds analyzed as for the 30 s/well fractions. At all carrier solvent flow rates tested, the GC peaks were collected into one or sometimes two fractions. A hexane solvent flow rate of 340 μL/min was chosen for further studies. Fractionation of M12 was also performed at different helium carrier gas flow rates (1.0, 2.5 to 4.4 mL/min). Both high-and low-resolution fractionations were performed. The results showed that a recovery per compound of 80% or more is achieved in one analytical run for most compounds. The two higher flow rates gave slightly better recoveries. Performing a Student t test on the data revealed that a significant difference is observed between 2.5 mL/min and 4.4 mL/min. The highest flow rate tested (4.4 mL/min) showed a significant delay in compound elution due to the highest backpressure at the end of the GC column. Figure 2 shows the results obtained. At 6.5 s/well resolution, no effect at the resolution was observed. In only a few cases, a peak was distributed over more than one fraction. A flow rate of 2.5 mL was applied for further studies. The length and inner diameter of the outlet carrier capillary and the position of the Y-union in the GC oven were shown not to have significant influence on recovery and resolution. Details can be found in the Supplementary material. Optional cooling of the outlet carrier capillary was achieved using an in-house-built cooling device by putting 20 cm of the outlet carrier capillary in direct contact with coolant (solid carbon dioxide at −80 °C or a solid CO 2 /acetonitrile mixture at −40 °C). Poor repeatability of the recovery was observed during tests at −80 °C between subsequent measurements. Some measurements with cooling at −80 °C gave good recoveries. Good recovery was obtained with −40 °C coolant (77 ± 14%), but an equally good recovery (76 ± 15%) was achieved by cooling at ambient air (20 °C).
In conclusion, the optimized conditions were 2.5 mL/min helium carrier gas, 340 μL/min hexane carried liquid flow, and 6.5 s/well fractionation into a white, nontransparent 96-well MTP.
Performance of the Analytical System after Optimization
After parameter optimization, the performance of the fractionation system was evaluated from recovery and resolution by fractionation of the M12 mixture under optimized conditions (6.5 s/well). The results are summarized in Figure 3 . Good resolution is achieved for early eluting compounds like 2,2′-DBB, FCP, CCP and B, which are collected as one compound per well (Fig. 3A) , whereas late eluting compounds like the coeluting isomers CHT-a and CHT-b, and PM-a and PM-b are distributed over a few wells (Fig. 3B) . A 2D representation of Figure 3B including error bars is shown in the Supplementary material Figure S3 . As the early eluting compounds are fractionated mostly in single fractions of 6.5 s, this demonstrates very limited post column band broadening of the system for these compounds. The recoveries observed in the high-resolution fractionation, however, are (systematically) lower than for fraction collection of a complete GC run into one container, or the 30 s resolution fractionation. This is most likely due to well to well movements that comprise relatively less time than in case of high 6.5 s resolution fractionation. Furthermore, evaporation effects of the low boiling compounds are stronger, because the high resolution leads to a much smaller volume of carrier liquid per well. Fractionation with 3 s/well results in distribution of early eluting compounds over two wells (see Supplementary material Figure S4 ). A shortcoming of GC using capillary columns is the low sample-loading amount. To address this shortcoming briefly, we performed repeated fractionation of the same sample on the same well plate, which demonstrated very repeatable fractionation of this sample over the same wells after repeated injections. In the Supplementary material, Figure S5 shows the results of the first five compounds in the M12 mixture fractionated 1, 3, and 5 times over the same wells. Figure S5 clearly shows that repeated fractionation of a sample over the same wells is possible, thus allowing up-concentration of the fractions by repeated fractionations. DR-LUC Bioassay with PAH standards An innovative way for cell seeding of adherent cells is applied in this study. In the postcolumn bioassay, the adherent cells are post-GC-fractionation seeded directly onto the dried fractions. In order to avoid nonspecific binding of the fractionated compounds to the wells, DMSO was deposited in the wells prior to fractionation. After evaporation of the carrier solvent, the often very nonpolar analytes reside in the thin DMSO film at the bottom of the wells, which facilitates dissolving during the assay. Figure 4A , BaP was fractionated over multiple wells, thus lowering the actual concentrations in the wells. Fractionation time was plotted against RLU per fraction to generate reconstructed bioactivity chromatograms. Figure 4A shows four superimposed bioassay chromatograms from averaged duplicates of the four BaP concentrations analyzed. Bioactivity peaks were observed in the 550-600 s fractionation time range in a concentration response manner. The increased peak broadening at the higher BaP concentrations were found to be due to column overloading and not the result of fractionation. (This was independently demonstrated by GC-FID analysis; data not shown.) These results demonstrate the potential of direct post-GC column bioactivity screening without further chemical sample workup or preanalysis steps.
Subsequently, a mixture containing 16 PAHs (5 ppm each) was analyzed. The resulting concentrations in the bioassay are at least a hundred fold lower than the injected concentrations since 1 μL is injected and the bioassay is performed in wells with 100 μL assay volume, i.e., medium and cells. Figure 4B shows the superimposed bioactivity chromatograms of a duplicate. In the bioactivity chromatograms obtained, several peaks can be clearly identified. The upper trace is the total-ion chromatogram (TIC) from GC-MS, obtained in parallel, from which the (partly coeluting) bioactive PAHs can be identified. An expanded view of the bioactive area between 11 and 18 min is shown in the Supplementary Material Figure S6 . The bioactivity peak at 14.0 min corresponds to benz[a]anthracene (8) and/or chrysene (9). Machala et al. [23] showed that chrysene is more potent and is thus expected to give the largest contribution of the two. The rather broad bioactivity peak at 15 Figure S7A ), it was found that the double peak is due to overlapping indeno[1,2,3-cd]pyrene (14) and dibenz(a,h)anthracene (15) , which are both known to be bioactive toward the AhR [22] [23] [24] [25] [26] [27] . For all other PAHs analyzed, e.g., pyrene (7) and benzo[e]pyrene (12) , no bioactivity was found with our approach, which is in agreement with data from Murahashi et al. [22] and Machala et al. [23] . 
DR-LUC Bioassay with CRM-535 Samples
Finally, an environmental sample containing PAHs (CRM-535) was analyzed. The data obtained are shown in Figure 4C . An expanded view of the bioactive area between 11 and 18 min is shown in the Supplementary material Figure S6 . Comparison of the TIC shown in Figure 4Cwith that in Figure 4B shows that the PAH concentration in the CRM-535 sample was generally 3-4 times lower. In the reconstructed bioactivity chromatograms, measured in duplicate, several bioactivity regions are found. Next to an intense bioactivity peak at 15.2 min, smaller peaks are visible near 14.0 and 14.5 min. Based on parallel GC-MS analysis, the same bioactive PAHs as observed for the standard mixture are observed for CRM-535, except for the three low-molecular-weight PAHs acenaphthylene (1), fluorene (3), and anthracene Figure 4C ), small peaks were identified. The MS library search identified these peaks as 12-methylbenz[a]anthracene, 1-methylchrysene and triphenylene. The bioactivity of these compounds for the dioxin receptor was confirmed by Cheung et al. [28] . The CRM sample showed no bioactivity at 16.7 min while the PAH standard did. The CRM-535 sample contained both compounds responsible for bioactivity in this area too, but in a lower indeno 
Conclusions
We have developed, optimized and validated a postcolumn GC fractionation system enabling bioactivity assessment of 6.5 s fractions eluting from the GC column. The system allows fraction collection in 96-well MTP, thus enabling the collection of far more fractions than possible with commercial GC fractionation devices. Our technology shows robust behavior to a large range of variables tested and provides good recovery and resolution in fractionation. The GC fractionation setup was combined with a postcolumn DR-LUC bioassay to test bioactivity of individual compounds in a synthetic PAH mixture and in a commercial CRM-535 sample. In this, our postfractionation cell-seeding approach allowed for straightforward analysis without additional dilution and/or sample-handling steps for cellular assaying. Several bioactive PAHs were found in the PAH mixture and the CRM-535 sample, identified using parallel GC-MS analysis. This approach holds great promise for systematic application in EDA. One disadvantage of capillary GC is the low sample load, which can hamper postcolumn detection of bioactives when using bioassays less sensitive than the DR-LUC. This problem may be circumvented by using packed GC columns or, as demonstrated in this work by us, by fractionating multiple times in the same well plate.
Supplementary material GC ECD analysis for recovery determination of collected fractions.
Preparation for recovery determination of collected fractions
In order to determine the recovery of the fractionated analytes of mixture M12, the entire well plate was dried by a gentle stream of nitrogen until near dryness. Then, each well was filled with 200 DL nAhexane, allowed to equilibrate for 30 sec and was then reAsuspended seven times with a GC syringe (Hamilton GASTIGHT 250 DL, Model 1725 Cemented NDL). Next, the content of each well was transferred to Aluglas 1.5 ml Amber, Wide Opening GC vials (32 × 11.6 mm) containing an insert (Aluglas 0.1 ml MicroAinsert, 29 × 5.7 mm with plastic spring). To this solution, 50 Dl of 10 A8M standard (lindane) was added. The resulting solution was then resuspended 5 times before capping the vials with Aluglas UltraClean Closure: 9mm polypropylene head, Silicone/PTFE septum caps for analysis. All fractions were subsequently analyzed by Gas Chromatography Electron Capture Detector (GCAECD) for recovery analysis. The peak areas of the analytes measured were corrected by using the standard (lindane).
Instrumental
The GC ECD system consisted of a Hewlett Packard (HP) 6890 series, a HP MicroAcell Electron Capture Detector (HAECD) and a Hewlett Packard 6890 series auto injector controlled by HP GC ChemStation software. The injection port type was split/splitless and the port was equipped with a 11 mm Agilent septum and lined with a Restek Sky 4.0mm ID Single Taper/Gooseneck Inlet Liner (4.0 x 6.5 x 78.5 mm). The column used was a FactorFour™ VFA5ms (5% phenyl/95%dimethylpolysiloxane) 30m x 0.37 mm x 0.25 Hm I.D. capillary column.
System parameters
The injection volume as 1 Dl with the injection port set at 300°C in splitless mode. To fully inject the sample, purge to split vent was started 2.0 min after injection with 20 mL/min helium. The GC oven was programmed from 65°C (hold time 2.00 min) to 300°C (hold time 2.00 min) at 15°C/min. Praxair 5.0 grade helium (Vlaardingen, The Netherlands) was used as carrier gas and was run in constant column flow mode. When using a flow rate of 4.4 mL/min, this resulted in a column head pressure of 250 kPa at 65°C. The ECD was run under constant makeup flow mode with Praxair 5.0 nitrogen (Vlaardingen, The Netherlands) at 30 mL/min. Detector sampling rate was set to 50 Hz at a temperature of 310°C. Chromatograms were manually integrated using HP ChemStation version 7.0.
Post fractionation bioassay analysis
GC fractionation
For BaP fractionation, modifications to the GC program and system were done: 100°C (hold time 1.00 min) to 300°C (hold time 8.00 min) at 40°C/min. Now, an ATAS OPTIC II injector was used to allow for large volume injections or programmed temperature injections. The ATAS injector, which was not controlled by HP ChemStation, was pressure programmed from 170 kPa (hold 1 min) to 270 kPa (hold 8 min) at 20 kPa/min. The pressure programming was performed since the OPTIC II does not support continuous flowmode and is not connected to the HP GC oven. The ATAS Optic II inlet pressure was programmed to maintain a constant flow at different oven temperatures, in order to match the program calculated by the HP ChemStation software. This calculation was performed by running a blank on the unmodified 6890 series GC and storing the inlet pressure profile. For PAH fractionation, the OPTIC II injector was also used. The oven temperature program was adjusted to achieve baseline separation for most compounds. After injection, the oven was held at 80°C for 2 min, then at 30°C/min to 150°C and further at 15°C to 190°C, at which it was held for 2 min, then the temperature was raised to 270°C at 25°C/min and subsequently to 285°C at 10°C/min. Finally the temperature was raised to 320°C at 30°C/min, at which it was held (3 min) until the end of the run (17.87 min). Because the OPTIC II software does not support more than four pressure program points, the profile was simplified to best match the continuous flow program calculated by HP ChemStation. For this, the pressure was set at 177.0 kPa and held for 120 sec followed by raising to 240 kPa in 330s, raising to 312 kPa in 442s and finally held at 312 kPa for 181s.
GC-MS analysis of PAH standards and the CRM samples
For PAH and CRM analysis on GCAMS, identical methods were used to allow correlation between peaks. The injection was performed using an autoinjector with a 300°C injection port temperature in splitless mode. The PAH standard was diluted ten times and then injected, resulting in a 2.5 ppm injection. Purge to vent was set at 2.0 min with 50 mL/min Helium and column flow at 2.5 mL/min Helium. Temperature programming for oven was initially at 80°C (hold 2 min) and with 30°C/min to 150°C followed by 15°C/min to 190°C (hold 2 min). The hold was followed by 25°C/min ramp to 270°C, 10°C/min to 285°C and 30°C/min to 320°C at which the temperature was held for 10 min. The oven was then cooled to 50°C/min. Quadrupole MS detection parameters were 200°C for quadrupole and 250°C for source. EM volts was set at 1635 with a solvent delay at 3.0 min. Full scan mode was utilized between m/z = 50 and m/z = 300.
Outlet capillary length and diameter
Effects of the length of the outlet carrier capillary were assessed by cutting the respective capillary in half, resulting in a capillary of 54 cm, and reconnecting it. Afterwards, a 6.5s fractionation was performed with M12 collecting only the first 50 fractions for recovery and resolution tests. Results showed no significant change in recovery and resolution. Recovery averaged from two measurements was 83% ± 1%. All compounds were collected in the same fraction numbers as measurements with 117 cm of outlet. Next, the carrier capillary was removed and replaced by an equal length (117 cm) capillary with a larger ID of 320 Dm instead of 250 Dm. With this setup, a 6.5s fractionation was performed using M12 and collecting the first 50 fractions. Similar results were obtained: the average recovery for two fractionations was 88% ± 3%, with approximately the same elution times.
Depth of YAsplit in GC oven
In all previous experiments, the YAsplit was placed as high as possible in the GC oven, effectively placing it 1 cm near oven ceiling (and exit for the outlet capillary). In the current experiment, the YAsplit was lowered in the GC oven to 20 cm beneath the oven ceiling. Since in the current case, both the hexane flows (in and out) had a longer contact time in the oven, differences due to evaporation speed of hexane might occur. When the YAsplit was lowered in the GC oven, the average recovery was 85% ± 11% as compared to 83% ± 2% for measurement at 1 cm depth. There was however a notable difference between 1cm and 20cm measurements when looking at retention time shifts. The chromatograms and recovery/peak profiles were near equal, although there appeared to be a delay of ~13 more seconds in all collected fractions for the 20 cm depth measurements. The resolutions remained about the same effectively collecting all eluting compounds mostly in one or two fractions. Figure 2A lists the compounds in order of elution (the most upper compound being the first compound to elute from the column).The results show that a recovery per compound of 80% or more is achieved in one analytical run for most compounds. Figure S2B . Variation of the flow rate of the carrier solvent in high resolution demonstrated for five compounds. In this graph, different flow rates were tested at high resolution (6.5 sec/well) fractionation. The resulting recovery per fraction is on the y-axis. The fraction time from injection is shown on the x-axis. As can be seen, higher flow rates cause a larger retention time caused by backpressure on the exit of the GC column from the carrier solvent pump. Thus, although the fluid is able to pass through the capillary quicker, it is slowed by the build-up of pressure in the split. Recovery wise there is no significant difference between lower and higher flow rates. At higher flow rates there are fewer fractions per peak, reflecting slightly sharper peaks. Recoveries and standard deviations are depicted in Table S1 . Figure S4 . First three peaks eluted from mixture M12 fractionated in 3.0 sec high resolution. In this figure, the resolution is more than double the resolution used in Figures 4A and 4B . The peaks shown correspond to the first three peaks in Figure 4A . Again, recovery in percentage is plotted on the y-axis while elution time is shown on the x-axis in seconds. Peaks are now fractionated in two fractions. Recoveries are lower than for 6.5 sec/well fractionation because of evaporation effects and well to well movement effects. Figure 4B and Figure  4C . Data has been plotted in an identical way where the MS data is superimposed on the bioassay data. 34% ± 7% 69% ± 18% 54% ± 21% 52% ± 17% 120% ± 44% 76% ± 10% 38% ± 2% 3% ± 2%
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